140 results
424B5
TCON
TRACON Pharmaceuticals Inc
12 Apr 24
Prospectus supplement for primary offering
4:36pm
;
the potential benefits of our collaboration arrangements and our ability to enter into additional collaboration arrangements;
the ability of our … benefits associated therewith;
the timing of, and our ability to obtain and maintain, regulatory approvals for our product candidates;
the effects
8-K
EX-99.1
TCON
TRACON Pharmaceuticals Inc
20 Nov 23
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
8:05am
the benefits of CRO-independent clinical trial implementation that we enjoy at TRACON,” said Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer … , including the potential costs saving and other benefits related thereto; potential utility of product candidates; and TRACON’s business development
8-K
EX-99.1
rkhyz6z09s
9 Nov 23
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:05pm
8-K
0189aef sk46lzxf6d2f
20 Jun 23
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3
8:08am
8-K
EX-99.1
bsj ubrthcm8itoxzxgm
20 Jun 23
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3
8:08am
424B3
wxyl4nl 04qma
31 May 23
Prospectus supplement
4:21pm
8-K
EX-99.1
mahddha
14 Sep 22
Other Events
8:09am
8-K
EX-10.1
2bs8bv38mhr
6 Sep 22
Entry into a Material Definitive Agreement
8:11am